TrialBlood2025

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.